{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:19:45Z","timestamp":1791987585179,"version":"4.4.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-67345-9","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T01:35:26Z","timestamp":1765848926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Concurrent PIK3CA mutant promotes cachexia through inflammatory signaling in EGFR mutant lung cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Meiting","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4295-6371","authenticated-orcid":false,"given":"Xinlei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7300-6604","authenticated-orcid":false,"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3960-0068","authenticated-orcid":false,"given":"Luonan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0891-6390","authenticated-orcid":false,"given":"Hongbin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"67345_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F. & Heist, R. S. Lung cancer. Lancet 398, 535\u2013554 (2021).","journal-title":"Lancet"},{"key":"67345_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Cancer Genome Atlas Research, N","year":"2014","unstructured":"Cancer Genome Atlas Research, N Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543\u201350 (2014).","journal-title":"Nature"},{"key":"67345_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature11404","volume":"489","author":"Cancer Genome Atlas Research, N","year":"2012","unstructured":"Cancer Genome Atlas Research, N Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519\u201325 (2012).","journal-title":"Nature"},{"key":"67345_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13334-8","volume":"10","author":"C Ghezzi","year":"2019","unstructured":"Ghezzi, C. et al. A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells. Nat. Commun. 10, 5444 (2019).","journal-title":"Nat. Commun."},{"key":"67345_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07685-y","volume":"16","author":"L Liu","year":"2025","unstructured":"Liu, L. et al. Therapeutic efficacy of TMTP1-modified EVs in overcoming bone metastasis and immune resistance in PIK3CA mutant NSCLC. Cell Death Dis. 16, 367 (2025).","journal-title":"Cell Death Dis."},{"key":"67345_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101116","volume":"22","author":"J Zhang","year":"2019","unstructured":"Zhang, J. et al. Tumoral NOX4 recruits M2 tumor-associated macrophages via ROS\/PI3K signaling-dependent various cytokine production to promote NSCLC growth. Redox Biol. 22, 101116 (2019).","journal-title":"Redox Biol."},{"key":"67345_CR7","doi-asserted-by":"publisher","first-page":"e003402","DOI":"10.1136\/jitc-2021-003402","volume":"10","author":"NB Collins","year":"2022","unstructured":"Collins, N. B. et al. PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. J. Immunother Cancer 10, e003402 (2022).","journal-title":"J. Immunother Cancer"},{"key":"67345_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2019.02.002","volume":"59","author":"R Arafeh","year":"2019","unstructured":"Arafeh, R. & Samuels, Y. PIK3CA in cancer: the past 30 years. Semin Cancer Biol. 59, 36\u201349 (2019).","journal-title":"Semin Cancer Biol."},{"key":"67345_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","volume":"15","author":"F Janku","year":"2018","unstructured":"Janku, F., Yap, T. A. & Meric-Bernstam, F. Targeting the PI3K pathway in cancer: are we making headway?. Nat. Rev. Clin. Oncol. 15, 273\u2013291 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"67345_CR10","doi-asserted-by":"publisher","first-page":"101430","DOI":"10.1016\/j.gendis.2024.101430","volume":"12","author":"Y Wang","year":"2025","unstructured":"Wang, Y., Rozen, V., Zhao, Y. & Wang, Z. Oncogenic activation of PI K3 CA in cancers: emerging targeted therapies in precision oncology. Genes Dis. 12, 101430 (2025).","journal-title":"Genes Dis."},{"key":"67345_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj, G. & Manning, B. D. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat. Rev. Cancer 20, 74\u201388 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"67345_CR12","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/nm.1890","volume":"14","author":"JA Engelman","year":"2008","unstructured":"Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351\u20136 (2008).","journal-title":"Nat. Med."},{"key":"67345_CR13","doi-asserted-by":"publisher","first-page":"e88291","DOI":"10.1371\/journal.pone.0088291","volume":"9","author":"L Wang","year":"2014","unstructured":"Wang, L. et al. PIK3CA mutations frequently coexist with EGFR\/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR\/KRAS wildtype subgroup. PLoS ONE 9, e88291 (2014).","journal-title":"PLoS ONE"},{"key":"67345_CR14","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1158\/1535-7163.MCT-11-0692","volume":"11","author":"JE Chaft","year":"2012","unstructured":"Chaft, J. E. et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol. Cancer Ther. 11, 485\u201391 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"67345_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","volume":"19","author":"F Skoulidis","year":"2019","unstructured":"Skoulidis, F. & Heymach, J. V. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat. Rev. Cancer 19, 495\u2013509 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"67345_CR16","doi-asserted-by":"publisher","first-page":"e06907","DOI":"10.7554\/eLife.06907","volume":"4","author":"AM Unni","year":"2015","unstructured":"Unni, A. M., Lockwood, W. W., Zejnullahu, K., Lee-Lin, S. Q. & Varmus, H. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. Elife 4, e06907 (2015).","journal-title":"Elife"},{"key":"67345_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwad028","volume":"10","author":"S Tang","year":"2023","unstructured":"Tang, S. et al. Counteracting lineage-specific transcription factor network finely tunes lung adeno-to-squamous transdifferentiation through remodeling tumor immune microenvironment. Natl. Sci. Rev. 10, nwad028 (2023).","journal-title":"Natl. Sci. Rev."},{"key":"67345_CR18","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1038\/onc.2016.385","volume":"36","author":"C Ambrogio","year":"2017","unstructured":"Ambrogio, C., Barbacid, M. & Santamaria, D. In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma. Oncogene 36, 2309\u20132318 (2017).","journal-title":"Oncogene"},{"key":"67345_CR19","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1158\/2159-8290.CD-20-1385","volume":"11","author":"G Foggetti","year":"2021","unstructured":"Foggetti, G. et al. Genetic determinants of EGFR-driven lung cancer growth and therapeutic response in vivo. Cancer Discov. 11, 1736\u20131753 (2021).","journal-title":"Cancer Discov."},{"key":"67345_CR20","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nature06030","volume":"448","author":"H Ji","year":"2007","unstructured":"Ji, H. et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 448, 807\u201310 (2007).","journal-title":"Nature"},{"key":"67345_CR21","doi-asserted-by":"publisher","first-page":"e20232028","DOI":"10.1084\/jem.20232028","volume":"221","author":"Z Qin","year":"2024","unstructured":"Qin, Z. et al. EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation. J. Exp. Med. 221, e20232028 (2024).","journal-title":"J. Exp. Med."},{"key":"67345_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","volume":"15","author":"K Fu","year":"2022","unstructured":"Fu, K., Xie, F., Wang, F. & Fu, L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J. Hematol. Oncol. 15, 173 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"67345_CR23","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress, K. S. et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21, 560\u20132 (2015).","journal-title":"Nat. Med."},{"key":"67345_CR24","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst, R. S., Morgensztern, D. & Boshoff, C. The biology and management of non-small cell lung cancer. Nature 553, 446\u2013454 (2018).","journal-title":"Nature"},{"key":"67345_CR25","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.21.01626","volume":"40","author":"AC Tan","year":"2022","unstructured":"Tan, A. C. & Tan, D. S. W. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J. Clin. Oncol. 40, 611\u2013625 (2022).","journal-title":"J. Clin. Oncol."},{"key":"67345_CR26","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1158\/1078-0432.CCR-18-1542","volume":"24","author":"X Le","year":"2018","unstructured":"Le, X. et al. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin. Cancer Res. 24, 6195\u20136203 (2018).","journal-title":"Clin. Cancer Res."},{"key":"67345_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35962-x","volume":"14","author":"J Chmielecki","year":"2023","unstructured":"Chmielecki, J. et al. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nat. Commun. 14, 1071 (2023).","journal-title":"Nat. Commun."},{"key":"67345_CR28","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1097\/JTO.0000000000000671","volume":"10","author":"J Eng","year":"2015","unstructured":"Eng, J. et al. Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas. J. Thorac. Oncol. 10, 1713\u20139 (2015).","journal-title":"J. Thorac. Oncol."},{"key":"67345_CR29","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1002\/cam4.852","volume":"5","author":"Z Song","year":"2016","unstructured":"Song, Z., Yu, X. & Zhang, Y. Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma. Cancer Med. 5, 2694\u20132700 (2016).","journal-title":"Cancer Med."},{"key":"67345_CR30","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.cell.2023.03.028","volume":"186","author":"M Ferrer","year":"2023","unstructured":"Ferrer, M. et al. Cachexia: a systemic consequence of progressive, unresolved disease. Cell 186, 1824\u20131845 (2023).","journal-title":"Cell"},{"key":"67345_CR31","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41571-023-00734-5","volume":"20","author":"JM Argiles","year":"2023","unstructured":"Argiles, J. M., Lopez-Soriano, F. J., Stemmler, B. & Busquets, S. Cancer-associated cachexia - understanding the tumour macroenvironment and microenvironment to improve management. Nat. Rev. Clin. Oncol. 20, 250\u2013264 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"67345_CR32","doi-asserted-by":"publisher","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","volume":"4","author":"VE Baracos","year":"2018","unstructured":"Baracos, V. E., Martin, L., Korc, M., Guttridge, D. C. & Fearon, K. C. H. Cancer-associated cachexia. Nat. Rev. Dis. Prim. 4, 17105 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"67345_CR33","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/jcsm.12206","volume":"8","author":"A Bye","year":"2017","unstructured":"Bye, A. et al. Muscle mass and association to quality of life in non-small cell lung cancer patients. J. Cachexia Sarcopenia Muscle 8, 759\u2013767 (2017).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"67345_CR34","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/sj.bjc.6601781","volume":"90","author":"PJ Ross","year":"2004","unstructured":"Ross, P. J. et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?. Br. J. Cancer 90, 1905\u201311 (2004).","journal-title":"Br. J. Cancer"},{"key":"67345_CR35","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1002\/jcsm.12967","volume":"13","author":"C de Jong","year":"2022","unstructured":"de Jong, C. et al. The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients. J. Cachexia Sarcopenia Muscle 13, 1554\u20131564 (2022).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"67345_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43866-5","volume":"13","author":"J Jin","year":"2023","unstructured":"Jin, J., Visina, J., Burns, T. F., Diergaarde, B. & Stabile, L. P. Male sex and pretreatment weight loss are associated with poor outcome in patients with advanced non-small cell lung cancer treated with immunotherapy: a retrospective study. Sci. Rep. 13, 17047 (2023).","journal-title":"Sci. Rep."},{"key":"67345_CR37","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41591-023-02232-8","volume":"29","author":"O Al-Sawaf","year":"2023","unstructured":"Al-Sawaf, O. et al. Body composition and lung cancer-associated cachexia in TRACERx. Nat. Med 29, 846\u2013858 (2023).","journal-title":"Nat. Med"},{"key":"67345_CR38","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1002\/jcsm.13095","volume":"13","author":"C Oswalt","year":"2022","unstructured":"Oswalt, C. et al. Associations between body mass index, weight loss and overall survival in patients with advanced lung cancer. J. Cachexia Sarcopenia Muscle 13, 2650\u20132660 (2022).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"67345_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.chest.2019.04.115","volume":"156","author":"M Yang","year":"2019","unstructured":"Yang, M., Shen, Y., Tan, L. & Li, W. Prognostic value of sarcopenia in lung cancer: a systematic review and meta-analysis. Chest 156, 101\u2013111 (2019).","journal-title":"Chest"},{"key":"67345_CR40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/jcsm.12253","volume":"9","author":"DS Mytelka","year":"2018","unstructured":"Mytelka, D. S., Li, L. & Benoit, K. Post-diagnosis weight loss as a prognostic factor in non-small cell lung cancer. J. Cachexia Sarcopenia Muscle 9, 86\u201392 (2018).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"67345_CR41","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nrc2192","volume":"7","author":"KK Frese","year":"2007","unstructured":"Frese, K. K. & Tuveson, D. A. Maximizing mouse cancer models. Nat. Rev. Cancer 7, 645\u201358 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"67345_CR42","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/nprot.2009.95","volume":"4","author":"M DuPage","year":"2009","unstructured":"DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064\u201372 (2009).","journal-title":"Nat. Protoc."},{"key":"67345_CR43","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12, 489\u201395 (2011).","journal-title":"Lancet Oncol."},{"key":"67345_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03901-5","volume":"21","author":"SS Cury","year":"2023","unstructured":"Cury, S. S. et al. Low muscle mass in lung cancer is associated with an inflammatory and immunosuppressive tumor microenvironment. J. Transl. Med. 21, 116 (2023).","journal-title":"J. Transl. Med."},{"key":"67345_CR45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-023-01429-1","volume":"16","author":"D Wang","year":"2023","unstructured":"Wang, D. et al. LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia. J. Hematol. Oncol. 16, 30 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"67345_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111934","volume":"42","author":"FA Graca","year":"2023","unstructured":"Graca, F. A. et al. Progressive development of melanoma-induced cachexia differentially impacts organ systems in mice. Cell Rep. 42, 111934 (2023).","journal-title":"Cell Rep."},{"key":"67345_CR47","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","volume":"16","author":"KC Fearon","year":"2012","unstructured":"Fearon, K. C., Glass, D. J. & Guttridge, D. C. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 16, 153\u201366 (2012).","journal-title":"Cell Metab."},{"key":"67345_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky043","volume":"2","author":"SM Judge","year":"2018","unstructured":"Judge, S. M. et al. Skeletal muscle fibrosis in pancreatic cancer patients with respect to survival. JNCI Cancer Spectr. 2, pky043 (2018).","journal-title":"JNCI Cancer Spectr."},{"key":"67345_CR49","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.celrep.2019.07.016","volume":"28","author":"EE Talbert","year":"2019","unstructured":"Talbert, E. E. et al. Modeling human cancer-induced cachexia. Cell Rep. 28, 1612\u20131622.e4 (2019).","journal-title":"Cell Rep."},{"key":"67345_CR50","first-page":"1699","volume":"23","author":"M Kimura","year":"2015","unstructured":"Kimura, M. et al. Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Support Care Cancer 23, 1699\u2013708 (2015).","journal-title":"Support Care Cancer"},{"key":"67345_CR51","doi-asserted-by":"publisher","first-page":"6853","DOI":"10.1038\/sj.onc.1203239","volume":"18","author":"HL Pahl","year":"1999","unstructured":"Pahl, H. L. Activators and target genes of Rel\/NF-\u03baB transcription factors. Oncogene 18, 6853\u20136866 (1999).","journal-title":"Oncogene"},{"key":"67345_CR52","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1126\/science.8052854","volume":"265","author":"E Kopp","year":"1994","unstructured":"Kopp, E. & Ghosh, S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265, 956\u20139 (1994).","journal-title":"Science"},{"key":"67345_CR53","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41586-023-06047-y","volume":"617","author":"SN Bilgic","year":"2023","unstructured":"Bilgic, S. N. et al. EDA2R-NIK signalling promotes muscle atrophy linked to cancer cachexia. Nature 617, 827\u2013834 (2023).","journal-title":"Nature"},{"key":"67345_CR54","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","volume":"391","author":"NC Turner","year":"2024","unstructured":"Turner, N. C. et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N. Engl. J. Med. 391, 1584\u20131596 (2024).","journal-title":"N. Engl. J. Med."},{"key":"67345_CR55","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","volume":"30","author":"SM Gough","year":"2024","unstructured":"Gough, S. M. et al. Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models. Clin. Cancer Res. 30, 3549\u20133563 (2024).","journal-title":"Clin. Cancer Res."},{"key":"67345_CR56","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1158\/2159-8290.CD-21-0072","volume":"12","author":"KW Song","year":"2022","unstructured":"Song, K. W. et al. RTK-dependent inducible degradation of mutant PI3Kalpha drives GDC-0077 (Inavolisib) efficacy. Cancer Discov. 12, 204\u2013219 (2022).","journal-title":"Cancer Discov."},{"key":"67345_CR57","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1158\/0008-5472.CAN-13-0681","volume":"73","author":"CL Trejo","year":"2013","unstructured":"Trejo, C. L. et al. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression. Cancer Res. 73, 6448\u201361 (2013).","journal-title":"Cancer Res."},{"key":"67345_CR58","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.1158\/0008-5472.CAN-15-1249","volume":"75","author":"S Green","year":"2015","unstructured":"Green, S., Trejo, C. L. & McMahon, M. PIK3CA(H1047R) accelerates and enhances KRAS(G12D)-driven lung tumorigenesis. Cancer Res. 75, 5378\u201391 (2015).","journal-title":"Cancer Res."},{"key":"67345_CR59","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41586-020-2214-z","volume":"580","author":"L Moore","year":"2020","unstructured":"Moore, L. et al. The mutational landscape of normal human endometrial epithelium. Nature 580, 640\u2013646 (2020).","journal-title":"Nature"},{"key":"67345_CR60","doi-asserted-by":"crossref","unstructured":"Herms, A. et al. Organismal metabolism regulates the expansion of oncogenic PIK3CA mutant clones in normal esophagus. Nat. Genet. 56, 2144\u20132157 (2024).","DOI":"10.1038\/s41588-024-01891-8"},{"key":"67345_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/srep35249","volume":"6","author":"SG Wu","year":"2016","unstructured":"Wu, S. G., Chang, Y. L., Yu, C. J., Yang, P. C. & Shih, J. Y. The role of PIK3CA mutations among lung adenocarcinoma patients with primary and acquired resistance to EGFR tyrosine kinase inhibition. Sci. Rep. 6, 35249 (2016).","journal-title":"Sci. Rep."},{"key":"67345_CR62","first-page":"629","volume":"1","author":"H Endoh","year":"2006","unstructured":"Endoh, H., Yatabe, Y., Kosaka, T., Kuwano, H. & Mitsudomi, T. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J. Thorac. Oncol. 1, 629\u201334 (2006).","journal-title":"J. Thorac. Oncol."},{"key":"67345_CR63","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1053\/j.gastro.2015.02.009","volume":"148","author":"M Chalabi-Dchar","year":"2015","unstructured":"Chalabi-Dchar, M. et al. Loss of somatostatin receptor subtype 2 promotes growth of KRAS-induced pancreatic tumors in mice by activating PI3K signaling and overexpression of CXCL16. Gastroenterology 148, 1452\u201365 (2015).","journal-title":"Gastroenterology"},{"key":"67345_CR64","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ccell.2016.12.003","volume":"31","author":"J Paul","year":"2017","unstructured":"Paul, J. et al. Simultaneous inhibition of PI3Kdelta and PI3Kalpha induces ABC-DLBCL regression by blocking BCR-dependent and -independent activation of NF-kappaB and AKT. Cancer Cell 31, 64\u201378 (2017).","journal-title":"Cancer Cell"},{"key":"67345_CR65","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1101\/gad.1662308","volume":"22","author":"HC Dan","year":"2008","unstructured":"Dan, H. C. et al. Akt-dependent regulation of NF-kappaB is controlled by mTOR and Raptor in association with IKK. Genes Dev. 22, 1490\u2013500 (2008).","journal-title":"Genes Dev."},{"key":"67345_CR66","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1093\/eurheartj\/ehr245","volume":"33","author":"R Li","year":"2012","unstructured":"Li, R. et al. Interleukin-7 induces recruitment of monocytes\/macrophages to endothelium. Eur. Heart J. 33, 3114\u201323 (2012).","journal-title":"Eur. Heart J."},{"key":"67345_CR67","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1158\/2159-8290.CD-11-0031","volume":"1","author":"H Ying","year":"2011","unstructured":"Ying, H. et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kappaB-cytokine network. Cancer Discov. 1, 158\u201369 (2011).","journal-title":"Cancer Discov."},{"key":"67345_CR68","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.bcp.2007.12.014","volume":"75","author":"L Zhao","year":"2008","unstructured":"Zhao, L., Lee, J. Y. & Hwang, D. H. The phosphatidylinositol 3-kinase\/Akt pathway negatively regulates Nod2-mediated NF-kappaB pathway. Biochem. Pharm. 75, 1515\u201325 (2008).","journal-title":"Biochem. Pharm."},{"key":"67345_CR69","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1158\/0008-5472.CAN-11-4141","volume":"72","author":"JE Hutti","year":"2012","unstructured":"Hutti, J. E. et al. Oncogenic PI3K mutations lead to NF-kappaB-dependent cytokine expression following growth factor deprivation. Cancer Res. 72, 3260\u20139 (2012).","journal-title":"Cancer Res."},{"key":"67345_CR70","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41577-021-00624-w","volume":"22","author":"H Baazim","year":"2022","unstructured":"Baazim, H., Antonio-Herrera, L. & Bergthaler, A. The interplay of immunology and cachexia in infection and cancer. Nat. Rev. Immunol. 22, 309\u2013321 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"67345_CR71","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.cell.2024.02.009","volume":"187","author":"C Swanton","year":"2024","unstructured":"Swanton, C. et al. Embracing cancer complexity: hallmarks of systemic disease. Cell 187, 1589\u20131616 (2024).","journal-title":"Cell"},{"key":"67345_CR72","doi-asserted-by":"publisher","first-page":"e169512","DOI":"10.1172\/jci.insight.169512","volume":"9","author":"DA Englund","year":"2024","unstructured":"Englund, D. A. et al. Senotherapeutic drug treatment ameliorates chemotherapy-induced cachexia. JCI Insight 9, e169512 (2024).","journal-title":"JCI Insight"},{"key":"67345_CR73","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.pccm.2024.02.003","volume":"2","author":"M Yue","year":"2024","unstructured":"Yue, M., Qin, Z., Hu, L. & Ji, H. Understanding cachexia and its impact on lung cancer and beyond. Chin. Med. J. Pulm. Crit. Care Med. 2, 95\u2013105 (2024).","journal-title":"Chin. Med. J. Pulm. Crit. Care Med."},{"key":"67345_CR74","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/23948","volume":"396","author":"MJ Yin","year":"1998","unstructured":"Yin, M. J., Yamamoto, Y. & Gaynor, R. B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396, 77\u201380 (1998).","journal-title":"Nature"},{"key":"67345_CR75","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1200\/JCO.2013.50.0322","volume":"31","author":"E Domingo","year":"2013","unstructured":"Domingo, E. et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J. Clin. Oncol. 31, 4297\u2013305 (2013).","journal-title":"J. Clin. Oncol."},{"key":"67345_CR76","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1056\/NEJMoa1207756","volume":"367","author":"X Liao","year":"2012","unstructured":"Liao, X. et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N. Engl. J. Med. 367, 1596\u2013606 (2012).","journal-title":"N. Engl. J. Med."},{"key":"67345_CR77","doi-asserted-by":"publisher","first-page":"S432","DOI":"10.1016\/j.annonc.2024.08.581","volume":"35","author":"U G\u00fcller","year":"2024","unstructured":"G\u00fcller, U. et al. 512O Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients: the phase III, prospective-randomized placebo-controlled multicenter SAKK 41\/13 trial. Ann. Oncol. 35, S432 (2024).","journal-title":"Ann. Oncol."},{"key":"67345_CR78","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.3390\/cancers12123787","volume":"12","author":"A Narasimhan","year":"2020","unstructured":"Narasimhan, A. et al. Identification of potential serum protein biomarkers and pathways for pancreatic cancer cachexia using an aptamer-based discovery platform. Cancers (Basel) 12, 3787 (2020).","journal-title":"Cancers (Basel)"},{"key":"67345_CR79","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u201320 (2014).","journal-title":"Bioinformatics"},{"key":"67345_CR80","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"67345_CR81","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"67345_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinforma. 14, 128 (2013).","journal-title":"BMC Bioinforma."},{"key":"67345_CR83","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).","journal-title":"Innovation"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67345-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67345-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67345-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:09:31Z","timestamp":1769213371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67345-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67345"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67345-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"704"}}